Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23.Read More
Roth Capital Partners launched coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a “buy” rating and a 12-month price target of $62. The stock closed at $47.52 on Oct. 18.Read More
Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.Read More
William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.Read More
An article on the Alzaforum website highlights IntelGenx (OTCQX:IGXT; TSXV:IGX) and its montelukast oral film candidate for the treatment of brain degenerative diseases, such as early-stage dementia.Read More
Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19.Read More
Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.Read More
William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5.Read More
Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of the board, effective immediately.Read More
Arbutus Biopharma (NASDAQ:ABUS) reported new results from the ongoing Phase 2 study of ARB-1467 in chronically infected HBV patients on stable nucleoside therapy, and plans to add a fourth cohort of patients to the trial.Read More
H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday.
Originally spun-off from Sandoz, Austria-based Nabriva has in-house expertise and broad, wholly-owned IP protection in the development of a novel pleuromutilin class of antibiotics.Read More
Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday.
Analyst Joseph Pantginis writes that Neuralstem has undergone a major restructuring and “we believe new management has righted the ship as it is now focused on small molecule approaches to neurological disorders.”Read More
Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) reported positive results from a Phase 2 study of ATB-346 in osteoarthritis (OA).
Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a dose of 250 mg, a dose that contains one-sixth of the typical daily dose of naproxen for treating OA.Read More
The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria.
"This marks another significant milestone for Revive and we look forward to initiating this Phase 2 study shortly," Fabio Chianelli, president, said in a statement.Read More
H.C. Wainwright has downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “neutral” from “buy” with a price target of $2.25. The stock closed at $2.44 on Tuesday.
Yesterday, CymaBay discontinued its exploratory Phase 2 study of MBX-8025 for the treatment of primary biliary cholangitis (PBC) because the study already met its objective of establishing proof-of-concept by showing marked improvements in markers of cholestasis.Read More
Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701.
The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have undergone radical prostatectomy for organ-localized prostate cancer.Read More
H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday.
BioPharmX’s lead product is Violet for the treatment of fibrocystic breast condition (FBC). It was launched in early 2015 and is currently sold over-the-counter in over 7,500 pharmacies in the U.S.Read More
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes.
TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects into a 24-week study, consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage.Read More